ERBB2 and breast carcinoma: Another example is in the research of Matusewicz et al., who proposed immunoliposomes targeted against breast cancer cells overexpressing human epidermal growth factor receptor 2 (HER2) encapsulating a highly lipophilic drug, simvastatin.